NCT01589419

A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer

An Open-Label Phase 1b Study of the Safety and Tolerability of Veliparib in Combination With Capecitabine and Radiation in Subjects With Locally Advanced Rectal Cancer (LARC)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: AbbVie (prior sponsor, Abbott) · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

An open-label, Phase 1b, dose escalation study evaluating the safety and tolerability of the PARP inhibitor Veliparib in combination with capecitabine and radiation in subjects with locally advanced rectal cancer (LARC).

Conditions

• Locally Advanced Rectal Cancer

Interventions

Type	Name	Description
DRUG	veliparib	see arm description
DRUG	capecitabine	see arm description
RADIATION	radiation	see arm description

Timeline

• Start date: 2012-06-01
• Primary completion: 2015-01-01
• Completion: 2015-01-01
• First posted: 2012-05-02
• Last updated: 2017-11-20

Locations

6 sites across 2 countries: United States, Australia